Future cardiology最新文献

{"title":"Linking hearts and minds: understanding the cardiovascular impact of bipolar disorder.","authors":"Darshini Shah, Bhupinder Singh, Fnu Varnika, Fremita Chelsea Fredrick, Anish Kumar Reddy Meda, Kanishk Aggarwal, Rohit Jain","doi":"10.1080/14796678.2024.2408944","DOIUrl":"10.1080/14796678.2024.2408944","url":null,"abstract":"<p><p>Bipolar disorder is a severe and recurring condition that has become a significant public health issue globally. Studies indicate a heightened risk and earlier onset of cardiovascular diseases among individuals with bipolar disorder, potentially increasing mortality rates. The chronic nature of bipolar disorder leads to disturbances across multiple systems, including autonomic dysfunction, over-activation of the hypothalamic-pituitary-adrenal axis and increased levels of peripheral inflammatory markers. These disruptions cause endothelial damage, the formation of plaques and blood clots, in addition to the medications used to treat bipolar disorder and genetic associations contributing to cardiovascular disease development. Understanding the complex interplay between bipolar disorder and cardiovascular events is essential for the prevention and effective management of cardiovascular conditions in individuals with bipolar disorder.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"709-718"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An analysis of retracted studies in cardiology in the last two decades.","authors":"Akash Sharma, Vidusha Karavadi, Harshini Suresh, Sowntappan Balasubramanian, Priyali Singh, Parteek Walia, U Venkatesh","doi":"10.1080/14796678.2024.2370698","DOIUrl":"10.1080/14796678.2024.2370698","url":null,"abstract":"<p><p><b>Background:</b> The aim of this study is to analyze retracted studies in cardiovascular field.<b>Methodology:</b> PubMed and Embase databases were used to identify retracted publications from 2002 to 2022. Various characteristics of articles were retrieved, and an analysis was performed using R software.<b>Results:</b> We finally included 979 articles. Authors from China have the highest number of retracted studies (35.5%), followed by the USA (22.1%), and Japan (4%). The most common causes of retraction are mistakes and honest errors (24.5%) and duplicate data (17.7%). From 2002 to 2022, there has been a significant increase in retracted studies and a decrease in the impact factor of journals, number of citations, and time to retraction.<b>Conclusion:</b> The trend of retracting publications in cardiology is increasing.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"471-477"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Second-generation everolimus-eluting intracoronary stents: a comprehensive review of the clinical evidence.","authors":"Ridhima Goel, Alessandro Spirito, Michael Gao, Birgit Vogel, Deborah N Kalkman, Roxana Mehran","doi":"10.2217/fca-2023-0092","DOIUrl":"10.2217/fca-2023-0092","url":null,"abstract":"<p><p>Percutaneous coronary intervention with implantation of second-generation drug-eluting stents (DES) has emerged as a mainstay for the treatment of obstructive coronary artery disease given its beneficial impact on clinical outcomes in these patients. Everolimus-eluting stents (EES) are one of the most frequently implanted second-generation DES; their use for the treatment of a wide range of patients including those with complex coronary lesions is supported by compelling evidence. Although newer stent platforms such as biodegradable polymer DES may lower local vessel inflammation, their efficacy and safety have not yet surpassed that of Xience stents. This article summarizes the properties of the Xience family of EES and the evidence supporting their use across diverse patient demographics and coronary lesion morphologies.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"103-116"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139642022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute coronary syndrome due to coronary vasospasm: a case report.","authors":"Andy Wang, Juliet Meir, Aaqib Malik, Tzvi Fishkin, Subo Dey, Julio A Panza, Syed Haidry","doi":"10.1080/14796678.2024.2392995","DOIUrl":"10.1080/14796678.2024.2392995","url":null,"abstract":"<p><p>Coronary vasospasm can lead to decreased cardiac perfusion and result in acute coronary syndrome. Here is a case of a 49-year-old man presented to the emergency department with epigastric pain and nausea with normal initial electrocardiogram. However, 6 h later, the patient experienced severe chest pain prompting a repeat electrocardiogram demonstrating inferior ST-segment elevation with troponin I levels peaked at 1.2 ng/ml (normal range: 0.00-0.02 ng/ml). Coronary angiography revealed angiographic stenosis in the left circumflex territory of a left dominant system which resolved with intracoronary nitroglycerin administration indicating ischemia with nonobstructive coronary arteries secondary to coronary vasospasm. He was discharged on isosorbide mononitrate and amlodipine therapy and had no recurrence of symptoms during follow-up.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"613-618"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Off-label uses of the Amplatzer Piccolo Occluder in children with congenital and acquired heart diseases.","authors":"Ashley Molloy, Neil Tailor, Ronak Naik, Nithya Swaminathan, Mohammed Absi, Anthony Merlocco, Jason Johnson, Shyam Sathanandam","doi":"10.1080/14796678.2024.2355057","DOIUrl":"10.1080/14796678.2024.2355057","url":null,"abstract":"<p><p><b>Aim:</b> The Amplatzer Piccolo Occluder (APO) is approved for patent ductus arteriosus (PDA) occlusion in infants weighing >700 g but could offer versatility to treat other lesions.<b>Methods:</b> Retrospective review of children in whom APO was utilized for defects other than PDA between January 2022 and June 2023.<b>Results:</b> The APO was used in nine patients; three for ventricular septal defects, four with coronary fistulas, one for a ventricular pseudoaneurysm and one where APO deployed within a fenestration of a previously placed Amplatzer Septal Occluder. All nine patients had successful occlusions without complications.<b>Conclusion:</b> The APO is a versatile device that can be used to treat various small diameter lesions in children besides the PDA for which it is currently approved for.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"459-470"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of long-term tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM): A plain language summary.","authors":"Martha Grogan, Margot K Davis, Maria G Crespo Leiro, Marla B Sultan, Balarama Gundapaneni, Franca Stedile Angeli, Mazen Hanna","doi":"10.1080/14796678.2024.2391250","DOIUrl":"10.1080/14796678.2024.2391250","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This summary explains some results of a study called ATTR-ACT and its ongoing long-term extension study that were published in the <i>European Journal of Heart Failure</i>. The purpose of ATTR-ACT was to find out if a drug called tafamidis is an effective treatment for people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). People took tafamidis or placebo for up to 2.5 years in ATTR-ACT (the initial study). A placebo looks like the study medicine but does not contain any active ingredients. After people completed the initial study, they could take part in the extension study. An extension study allows people to continue receiving treatment after the original clinical study ends and helps researchers understand how well a treatment works over a longer time period. This extension study allows people to receive tafamidis for up to an additional 5 years. People who took placebo in the initial study now receive tafamidis. People who took tafamidis in the initial study continue tafamidis treatment. Researchers looked at changes in peoples' ability to enjoy life ('quality of life') and heart failure symptoms since they started ATTR-ACT. Results are available for the first 2.5 years of the extension study.</p><p><strong>What are the key takeaways?: </strong>During the initial study, there was less worsening of quality of life and heart failure symptoms in people who took tafamidis compared to people who took placebo. In the extension study, quality of life and heart failure symptoms were maintained or nearly maintained in people who took tafamidis in the initial study. In people who started tafamidis in the extension study, quality of life and heart failure symptoms continued to worsen, but the worsening slowed down.</p><p><strong>What were the main conclusions reported by the researchers?: </strong>Tafamidis slows the worsening of quality of life and heart failure symptoms in people with ATTR-CM. People with ATTR-CM should start treatment early to receive the most benefit.<b>Clinical Trial Registration:</b> NCT01994889 (ATTR-ACT) (ClinicalTrials.gov).</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"595-603"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142283916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary intravascular lithotripsy: the tombstone of coronary calcium.","authors":"Chandrashekar Bohra, Amit Gulati, Amit Hooda","doi":"10.1080/14796678.2024.2411191","DOIUrl":"10.1080/14796678.2024.2411191","url":null,"abstract":"","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"669-670"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Get pumped for the new year with <i>Future Cardiology</i>: welcome to volume 20.","authors":"Ashling Cannon","doi":"10.2217/fca-2023-0130","DOIUrl":"10.2217/fca-2023-0130","url":null,"abstract":"","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-4"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy and correlation of bed and standing scale weights in monitoring volume status in heart failure patients.","authors":"Devin Skoll, Phillip Abarca, Vu Pham, Anushka Das, Clark Mantini, Han Tun, Helga Van Herle, Ajay Vaidya, Aaron M Wolfson, Michael W Fong","doi":"10.1080/14796678.2024.2340919","DOIUrl":"10.1080/14796678.2024.2340919","url":null,"abstract":"<p><p><b>Introduction:</b> Accurate volume status monitoring is crucial for effective diuretic therapy in patients with acute decompensated heart failure (ADHF). While guidelines recommend daily standing body weight measurement as an indicator of volume status, bed scales are commonly used in healthcare facilities.<b>Methods:</b> A method-comparison design was used to compare bed and standing scale weights among adults hospitalized with ADHF at Los Angeles County-University of Southern California Medical Center between March and April 2023.<b>Results & Conclusion:</b> Among 51 weight pairs from 43 participants, a clinically significant mean difference of 1.42 ± 1.18 kg was observed, exceeding the recommended threshold. Inaccuracies, with 71% showing differences >0.6 kg, highlight potential fluid management errors when relying on bed scales in ADHF hospitalizations.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"389-393"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and advances in device-related thrombus in left atrial appendage occlusion.","authors":"Takamasa Tanaka, Kenji Kawai, Christopher R Ellis, Mukta Srivastava, Rika Kawakami, Takao Konishi, Tatsuya Shiraki, Teruo Sekimoto, Renu Virmani, Aloke V Finn","doi":"10.1080/14796678.2024.2363063","DOIUrl":"10.1080/14796678.2024.2363063","url":null,"abstract":"<p><p>Oral anticoagulation therapy (OAC) is a mainstay for mitigating stroke and other embolic events in patients with atrial fibrillation (AF). Despite the demonstrated efficacy of OAC in reducing events, many patients are unable to tolerate OAC due to bleeding risks. Left atrial appendage occlusion (LAAO) devices were developed as implantable technologies to moderate stroke risk in patients with intolerance to OAC. Despite clinical data supporting near-comparable protection against thromboembolic events with OAC, device-related thrombus formation has emerged as a critical complication following LAAO that remains a potential limitation to the safety and efficacy of LAAO. Improved biocompatibility of LAAO devices with fluoropolymers, a well-established stent-coating technology used to reduce thrombus formation and promote endothelialization, may optimize outcomes after LAAO.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"343-358"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}